Ebselen: A Promising Repurposing Drug to Treat Infections Caused by Multidrug-Resistant Microorganisms

Table 3

In vitro antibacterial effect of ebselen on Gram-negative bacteria.

Microorganism	Strain	MIC (μg/mL)	Reference
E. coli	Clinical isolate (ESBL)	64–>128	[46]
	Clinical isolates (MβLs)
K. pneumonia	Clinical isolate (ESBL)	>128
	Clinical isolate (NDM-1)
P. aeruginosa	Clinical isolate	>128
Y. pseudotuberculosis	Yp III	(plus 0.5 μM Ag^+)	[63]
H. pylori	NCTC11637	3.13	[15]
	Clinical isolate
A. baumanii	ATCC 17978	32	[66]
E. coli	MG1655	128
Enterobacteriaceae	Reference strains	12.5–50	[43]
E. coli	ATCC 25922	274	[32]
S. marcescens	MTCC 2465	14	[67]
A. baumanii	ATCC BAA1605	16	[52]
E. coli O157:H7	ATCC 700728	32
K. pneumonia	ATCC BAA2146	64
P. aeruginosa	ATCC 9721	>256
S. Typhimurium	ATCC 700720	32

μM; MIC₉₀; MIC₅₀; ATCC: American Type Culture Collection; ESBL: extended-spectrum beta-lactamases; MβLs: metallo-beta-lactamases; MTCC: Microbial Type Culture Collection; NDM-1: New Delhi metallo-beta-lactamases.